First lung cancer treatment with BSD's MicroThermX ablation system delivered at Rhode Island Hospital

Feb 16 2011

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) today announced the successful delivery of its first lung cancer patient treatment with the MicroThermX^® Microwave Ablation System. The treatment was conducted by Damian E. Dupuy, M.D., at The Comprehensive Cancer Center at Rhode Island Hospital (Rhode Island Hospital) in Providence, Rhode Island. Dr. Dupuy utilized the 3 antenna synchronous phased array capability of the MicroThermX^® to deliver multiple ablations to a patient with a large cancerous tumor of the lung.

Referring to his first patient treatment, Dr. Dupuy stated, "The MicroThermX^® is the best generator that I have used. The unique ability of the system to provide real-time feedback on the forward power delivery to the tumor is invaluable to the physician. The system provides multiple benefits to physicians and patients, including the ability to deliver ablations using multiple antennas driven by a single generator, flexibility in treatment delivery, compact size, and ease of use."

Rhode Island Hospital is among the first in the nation to use BSD's innovative new microwave ablation system. BSD's initial product launch has focused on placement of a select number of systems with high-profile, interventional oncology, key opinion leaders. Rhode Island Hospital is a leading interventional oncology institution, and Dr. Dupuy, Director of Tumor Ablation at Rhode Island Hospital and a Professor of Diagnostic Imaging at The Warren Alpert Medical School of Brown University, is a key opinion leader in the field of ablation. Dr. Dupuy, a pioneer in the use of image-guided ablation, has helped broaden clinical applications of ablation to successfully combat cancer of the kidney, liver, lung, adrenal glands and skeleton. Dr. Dupuy is also a pioneer and expert in the use of the newer ablation technologies, including microwave ablation, and is currently the principal investigator of two National Cancer Institute funded multicenter trials on ablation.

Source BSD Medical Corporation